MORF's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.21 -- higher than merely 4.06% of US-listed equities with positive expected earnings growth.
MORF's went public 1.34 years ago, making it older than only 1.09% of listed US stocks we're tracking.
The ratio of debt to operating expenses for Morphic Holding Inc is higher than it is for about only 0.35% of US stocks.
If you're looking for stocks that are quantitatively similar to Morphic Holding Inc, a group of peers worth examining would be MGNX, VBLT, CRBP, FIXX, and CARA.
Morphic Holding, Inc. operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A. Springer in August 2014 and is headquartered in Waltham, MA.
Morphic Therapeutic (MORF) announces that collaboration partner and licensee AbbVie (ABBV) has exercised its option to develop its αvβ6 integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis ((IPF)) and additional indications.The license covers αvβ6 integrin specific inhibitors discovered from Morphic’s proprietary MInT Platform, including the compounds MORF-720 and...
Morphic Therapeutic (MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., president and chief executive officer, and Marc Schegerin, M.D., chief financial officer and chief operating officer, are scheduled to make a presentation at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference at 11:00 a.m. ET on Tuesday, June 23, 2020. Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer.
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each […]